Expression height and presence/absence of expression were assessed for (i) examples of potential “target genes.” As the aim of our manuscript was prospective testing of the GEP-R, these examples include AURKA, FGFR3, and IGF1R, for which at that time potential clinical grade inhibitors were foreseen, (ii) potential targets for immunotherapy, i.e., cancer testis antigens like CTAG1, MAGE1, and HM1.24, and (iii) genes frequently aberrantly or differentially expressed in myeloma. This evidence concerns the gene IGF1R and cancer.